Enzomenib

Enzomenib
Clinical data
Other namesDSP-5336
Identifiers
  • 5-fluoro-2-[4-[7-[(1S,3S,4R)-5-methylidene-2-azabicyclo[2.2.2]octane-3-carbonyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-N,N-di(propan-2-yl)benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC33H43FN6O3
Molar mass590.744 g·mol−1
3D model (JSmol)
  • CC(C)N(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C(=O)[C@@H]5[C@@H]6CC[C@H](N5)CC6=C
  • InChI=InChI=1S/C33H43FN6O3/c1-20(2)40(21(3)4)31(41)26-15-23(34)6-9-27(26)43-28-16-35-19-36-30(28)39-17-33(18-39)10-12-38(13-11-33)32(42)29-25-8-7-24(37-29)14-22(25)5/h6,9,15-16,19-21,24-25,29,37H,5,7-8,10-14,17-18H2,1-4H3/t24-,25+,29-/m0/s1
  • Key:JQHJEDMMWUIYCE-FVVBACEJSA-N

Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia.[1] It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins.[2] Enzomenib particularly in patients with KMT2A (MLL) rearrangements or NPM1 mutations.[3]

The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Orphan Drug designations to Enzomenib.[4]

References

  1. ^ "Enzomenib - Sumitomo Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Dempke WC, Desole M, Chiusolo P, Sica S, Schmidt-Hieber M (September 2023). "Targeting the undruggable: menin inhibitors ante portas". Journal of Cancer Research and Clinical Oncology. 149 (11): 9451–9459. doi:10.1007/s00432-023-04752-9. PMC 11798168. PMID 37103568.
  3. ^ "Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress". Sumitomo Pharma Co., Ltd. 14 June 2024.
  4. ^ Flaherty C (15 July 2024). "FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML". OncLive.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.